FDA-Drug2020-01-29Class II
Preferred Pharmaceuticals, Inc, Ranitidine Tablets, 150 mg, a) 30 count bottles (NDC: 68788-7388-3), b) 60 count bottles (NDC: 68788-7388-6), c) 90 count bottles (NDC: 68788-7388-9), d) 100 count bottles (NDC: 68788-7388-1)
Preferred Pharmaceuticals, Inc
Hazard
CGMP Deviations: Presence of NDMA impurity detected in product.
Sold states
Distribution to physicians in the following states: AL, AZ, CA, FL, GA, IN, and SC
Affected count
221,710 tablets
Manufactured in
1250 N Lakeview Ave Ste O, Anaheim, CA, United States
Products
Preferred Pharmaceuticals, Inc, Ranitidine Tablets, 150 mg, a) 30 count bottles (NDC: 68788-7388-3), b) 60 count bottles (NDC: 68788-7388-6), c) 90 count bottles (NDC: 68788-7388-9), d) 100 count bottles (NDC: 68788-7388-1)
Official notice
https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0796-2020Don't want to check this manually?
We email you a Sunday digest of new federal recalls relevant to parents — free, no credit card. Or upgrade to as-it-happens alerts for the brands you actually own.
Get the Sunday Brief